Tous Actualités
Suivre
Abonner Isotechnika Inc.

Isotechnika Inc.

Isotechnika Completes Recruitment for Phase III Psoriasis Trial

Edmonton, Canada (ots/PRNewswire)

Isotechnika Inc. announced
today that the Company has completed recruitment for its Canadian
Phase III psoriasis trial for its lead immunosuppressive compound,
ISA247. Of the 400 subjects enrolled in the trial, 207 subjects have
commenced treatment.
The Company received a "No Objection Letter" from Health Canada on
December 1, 2004 and commenced the trial on December 2, 2004. The
Phase III trial will be performed over a twenty-four week period at
thirty-two centres across Canada involving subjects with moderate to
severe psoriasis. It will be conducted as a randomised, double-blind
study with four dose arms. Of the 400 subjects, 100 subjects will
receive the high dose (0.4 mg/kg twice daily), 100 subjects will
receive the mid dose (0.3 mg/kg twice daily), 100 subjects will
receive the low dose (0.2 mg/kg twice daily) and 100 subjects will
receive placebo. Subsequent to the first 12 weeks, those subjects who
received placebo will move into the mid dose range dose of 0.3 mg/kg
twice daily for the remaining 12 weeks of the study.
"We are pleased that our recruitment has been completed in just
two months," stated Dr. Randall Yatscoff, Isotechnika's President and
Chief Operating Officer. "This indicates an unmet medical need for
people suffering from this debilitating disease. Isotechnika will
continue to focus its resources on advancing ISA247 for the treatment
of psoriasis."
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world-class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead drug, ISA247, presently referred to as
trans-ISA247, is an immunosuppressant that has successfully completed
a Phase II trial for psoriasis and Phase IIa trial for kidney
transplantation. The Company also has two additional
immunosuppressive compounds in its drug pipeline, TAFA93 and TKB662.
Both compounds are in early stage clinical development, Phase I and
pre-clinical respectively.
In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(TM) and Diatest(TM)
breath kits. The Helikit(TM), a (13)C breath test is used for the
detection of H.pylori, a bacterium that infects a large portion of
the population. The Diatest(TM), a (13)C glucose breath test is used
to measure insulin resistance.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
Forward-Looking Statements
This press release may contain forward-looking statements.
Forward- looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward- looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialise its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

Contact:

Dr. Randall Yatscoff, President & COO, Isotechnika Inc., Phone:
+1-780-487-1600 Ext.246, Fax: +1-780-484-4105, Email:
ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Senior
Manager, Corporate Communications & Investor Relations, Isotechnika
Inc., Phone: +1-780-487-1600 Ext. 243, Fax: +1-780-484-4105, E-mail:
sgillis-paulgaard@isotechnika.com. Archived images on this
organisation are available through CNW E-Pix at
http://www.newswire.ca. Images are free to members of The Canadian
Press. To request a free copy of this organisation's annual report,
please go to http://www.newswire.ca and click on reports@cnw

Plus de actualités: Isotechnika Inc.
Plus de actualités: Isotechnika Inc.
  • 02.12.2004 – 14:02

    Isotechnika Initiates Canadian Phase III Psoriasis Trial

    Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that a Canadian Phase III trial for its lead immunosuppressive drug candidate, ISA247 for the treatment of moderate to severe psoriasis has commenced. As of today, a total of 21 patients have been enrolled and dosing has begun. The Phase III trial will be performed over a twenty-four week period at thirty-three centers across Canada involving a ...

  • 03.11.2004 – 14:05

    Isotechnika Inc. Achieves all Endpoints in Multiple Ascending Dose Study for ISA247

    Edmonton, Canada, November 3 (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has successfully completed the multiple ascending dose study for its lead immunosuppressive drug, ISA247. The multiple ascending dose (MAD) study for ISA247 that commenced on June 3, 2004 involved a total of 43 subjects. The study, conducted by SFBC Anapharm in ...